Bupropion/mecamylamine - Cary Pharmaceuticals

Drug Profile

Bupropion/mecamylamine - Cary Pharmaceuticals

Alternative Names: INT-0003; INT-0003-2005; INT-0003/2005; INT-003-05; QuitPak; Smoking cessation therapy - Cary Pharmaceuticals

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cary Pharmaceuticals
  • Class Norbornanes; Propiophenones; Small molecules; Smoking cessation therapies
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Nicotinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Smoking withdrawal

Highest Development Phases

  • No development reported Smoking withdrawal

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Smoking-withdrawal in USA (PO, Tablet)
  • 28 Feb 2014 Cary Pharmaceuticals seeking partner for phase III and commercial development of bupropion/mecamylamine for Smoking withdrawal. www.carypharma.com
  • 28 Feb 2014 Cary Pharmaceuticals completes a phase I safety and tolerability trial in Smoking withdrawal in USA before February 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top